Thu, Mar 28, 2024
A A A
Welcome Guest
Free Trial RSS pod
Get FREE trial access to our award winning publications
Industry Updates

Venture capital-backed deals in healthtech companies hit $8.2bn in Q1 2020

Friday, May 29, 2020
Opalesque Industry Update - Prior to the outbreak of COVID-19, healthtech was already a sector of increasing interest among investors, said Preqin. But as a result of COVID-19, more alternative assets professionals are looking for opportunities in the healthtech sector, and there has been an uptick in venture capital dealmaking in the space.

Between January and March 2020, the total value of global venture-backed healthtech deals jumped by 76% from Q1 2019 reaching $8.2bn, the highest quarterly total on record. Activity has been dominated by North America, comprising 56% of the total number of deals, followed by Europe with 21% and Asia with 17%.

The largest venture-backed healthtech deal completed in Q1 2020 was the $285mn Series E financing held by ClassPass Inc. This momentum has continued into Q2, with a further $3.2bn in healthtech deals made since the start of April - at this pace, 2020 will be a record year for the sector by some distance.

Christopher Beales, Private Equity Spokesperson: "Healthtech was already an area of some interest to venture capital investors, as Preqin discussed at the start of the year. But the COVID-19 pandemic has thrown the potential of the sector into sharp relief. Remote consultations, prescription delivery, digital therapeutic and wellness classes - demand for next-generation healthcare solutions has boomed. As such, startups and investors are jumping to try and meet that need, and a sector that was already expanding has been given a real shot of adrenaline."

Key Healthtech Deals Facts:

• In our April 2020 survey of over 100 investors active in alternative assets, 36% said that they are targeting healthcare-focused investments in 2020 because of COVID-19's impact.

• Global venture-backed healthcare deal value increased from $4.7bn in Q1 2019, to $8.2 in Q1 2020.

• Regionally, in Q1 2020, 239 deals were completed in North America, 87 in Europe and 73 in Asia.

• The largest venture-backed healthtech deal completed in Q1 2020 was the $285mn Series E financing held by ClassPass Inc.

• In Q2 2020, as at 18th May 2020, 158 healthtech deals have been completed with a value of $3.2bn.

Article source - Opalesque is not responsible for the content of external internet sites

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Previous Opalesque Exclusives                                  
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. KKR raises $6.4bn for the largest pan-Asia infrastructure fund[more]

    Laxman Pai, Opalesque Asia: The New York-based global investment firm KKR has raised a record $6.4bn for its second Asia-focused infrastructure fund, underlining investors' continued appetite for private markets. According to a media release from the alternative assets manager, the figure top

  2. Bucking the trend, top hedge fund makes plans for a second SPAC[more]

    From Institutional Investor: SPACs aren't dead. At least not to the folks at Cormorant Asset Management. The life sciences firm, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company. Last week, the life sciences and biopharma speciali

  3. Benefit Street Partners closes fifth fund on $4.7 billion[more]

    Bailey McCann, Opalesque New York: Benefit Street Partners has closed its fifth flagship direct lending vehicle, BSP Debt Fund V, with $4.7 billion of investable capital across the strategy. Benefit Street invests primarily in privately originated, floating rate, senior secured loans. The fun

  4. 4 hedge fund themes that are working in 2024[more]

    From The Street: A poor earnings report from Tesla (TSLA) has not hurt the indexes on Thursday. The decline in Tesla stock, which is losing its position in the Magnificent Seven pantheon, is more than offset by strong earnings from IBM (IBM) and ServiceNow (NOW) . In addition, the much higher-t

  5. Opalesque Exclusive: A global macro fund eyes opportunities in bonds[more]

    Bailey McCann, Opalesque New York for New Managers: Munich-based ThirdYear Capital rebounded in 2023, following a tough year for global macro. The firm's flagship ART Global Macro strategy finished the year up 1